Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase NA 6Phase 1/2 5Phase 3 3Phase 2/3 3Phase 1 1

Status

Unknown 5Recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Gastric Adenocarcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Liver Neoplasms 1Liver Diseases 1Leukemia, Myeloid, Acute 1Immune Checkpoint Inhibition 1ESCC 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Bites and Stings 1Advanced Hepatocellular Carcinoma 1

Interventions

Radiosurgery 24lenvatinib 19Radiofrequency Ablation 16Hepatectomy 13Sorafenib 12Radiotherapy 9Surgical Procedures, Operative 8Magnetic Resonance Spectroscopy 7Bevacizumab 7sintilimab 6camrelizumab 6Immune Checkpoint Inhibitors 6Electroporation 6Blood Specimen Collection 6atezolizumab 5apatinib 5tislelizumab 4Yttrium-90 4Proton Therapy 4Oxaliplatin 4Liver Transplantation 4Doxorubicin 4Control Groups 4Cisplatin 4Chemoembolization, Therapeutic 4Catheter Ablation 4spartalizumab 3entecavir 3X-Rays 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase NA × Carcinoma, Hepatocellular × camrelizumab × Clear all
NCT06061276 2024-09-23

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Sun Yat-sen University

Phase NA Recruiting
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

NCT04559607 2023-12-18

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Zhongda Hospital

Phase NA Unknown
188 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05339581 2022-04-27

iPLENTY-pvtt

RenJi Hospital

Phase NA Unknown
78 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

The Central Hospital of Lishui City

Phase NA Unknown
176 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03914352 2019-04-16

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Cancer Hospital of Guangxi Medical University

Phase NA Unknown
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT03722875 2018-12-19

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Shanghai Zhongshan Hospital

Phase NA Unknown
45 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡